ProCE Banner Activity

Patient-Focused Interactive Treatment Tool on Prostate Cancer: Treatment Options From 5 Experts

Tool

Treatment Options for People With Prostate Cancer From 5 Experts

Released: November 22, 2023

Begin Activity

Share

Faculty

Tanya B. Dorff

Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Alicia Morgans

Alicia Morgans, MD, MPH

Associate ProfessorDana-Farber Cancer InstituteBoston, Massachusetts

Michael Schweizer

Michael Schweizer, MD

Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

David VanderWeele

David VanderWeele, MD, PhD

Associate Professor
Department of Hematology/Oncology
Northwestern University
Attending Physician
Department of Hematology/Oncology
Jesse Brown VA Medical Center
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC in partnership with ZERO Cancer

ProCE Banner

Supporters

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Lilly

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Partners

ZERO Prostate Cancer

ProCE Banner

Disclosure

Primary Author

Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

Tanya B. Dorff, MD: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Sanofi, SeaGen.

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Rana R. McKay, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Bristol-Myers Squibb, Bayer, Calithera, Caris, Dendreon, Eisaix, Exelixis, Johnson & Johnson, Lilly, Myovant, Merck, Novartis, Pfizer, Sanofi, Seagen, Sorrento, Telix, Tempus; research funding (paid to institution): Artera, Bayer, BMS, Exelixis, AstraZeneca, Oncternal, Tempus. 

Alicia Morgans, MD, MPH

Associate ProfessorDana-Farber Cancer InstituteBoston, Massachusetts

Alicia K. Morgans, MD, MPH: consultant/advisor/speaker: AAA, Astellas, AstraZeneca, Bayer, Dendreon, Foundation Medicine, Exelixis, Janssen, Lantheus, Myovant, Myriad, Novartis, Pfizer, Sanofi, SeaGen, Telix.

Michael Schweizer, MD

Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

Michael Schweizer, MD: consultant/advisor/speaker: AstraZeneca, PharmaIn, Sanofi; researcher (paid to institution): AstraZeneca, Ambrx, Bristol Myers Squibb, Epigenetix, Hoffman-La Roche, Immunomedics, Incyte, Janssen, Merck, Pfizer, SignalOne Bio, Tmunity, Xencoer, Zenith Epigenetics.

David VanderWeele, MD, PhD

Associate Professor
Department of Hematology/Oncology
Northwestern University
Attending Physician
Department of Hematology/Oncology
Jesse Brown VA Medical Center
Chicago, Illinois

David VanderWeele, MD, PhD: consultant/advisor/speaker: Astellas, Bayer, Exelixis, Janssen.